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INTRODUCTION
Advancement in quality of health care has
resulted in improved patient outcomes;
however, knowledge of delirium as well
as methods of treatment and its preven-
tion are not well known. The prevalence
of delirium in postoperative patients is
associated with an increase in mortality,
impaired recovery, and increased hospital
costs (Chu et al., 2011). Complex syn-
dromes, like delirium, are usually not asso-
ciated with a single independent cause but
instead with a number of different sources
(van Munster et al., 2011). Delirium is
defined by the Diagnostic and Statistical
Manual of Mental Disorders, fifth edition
(DSM-V) as a disturbance in attention
and awareness according to several criteria
(American Psychiatric Association, 2013).
Biomarkers are biochemical or molecular
traces related to the presence or severity
of a disease (Chu et al., 2011). Biomarkers
present before the onset of the disease can
be used as a risk marker, the rise and fall of
biomarkers during illness can be tracked as
a disease marker, and remaining biomark-
ers can be seen as an end product of a
disease (Chu et al., 2011). The aim of this
paper is to identify biomarkers that may
have a diagnostic and prognostic role in
delirium.
NEUROINFLAMMATION
There are many potential inflammatory
serum and genetic biomarkers to investi-
gate along with delirium and PD.However,
it may not be sufficient to simply ana-
lyze serum inflammatory proteins; a 2006
review noted multiple problems with
using inflammatory serum biomarkers as
a primary measure of inflammatory reac-
tion and delirium association, including
the large number of inflammatory cascade
proteins involved (levels of each can vary
on an individual basis) and the fact that
the cytokine response can be confounded
by many factors (age, type of insult,
comorbid conditions, etc.) (Munster et al.,
2011). A more promising strategy may
investigating delirium in conjunction with
the genetics underlying an individual’s
inflammatory response. A study investi-
gating Interleukin-6 (IL-6), Interleukin-8
(IL-8), and Interleukin-6 Receptor (IL-6R)
genetic variations and delirium, found no
polymorphisms associated with delirium
(Marcantonio et al., 2006; van Munster
et al., 2011). However, a preliminary case-
control investigation by the same research
group found a link between human brain
activity of microglia, astrocytes and IL-
6 and delirium, with elevated HLA-DR,
CD68, IL-6 being associated with an
increased prevalence of delirium, and the
biomarkers GFAP and IL-1β showing no
association (Munster et al., 2011). These
results suggest the possibility that there
could be an underlying mechanism asso-
ciated with brain-localized inflammation
precipitating delirium, a conclusion war-
ranting further investigation.
DOPAMINE RECEPTORS
Genetic variance in genes encoding
dopamine receptors has been studied in
possible relation to delirium. Genotyping
performed on DNA isolated from 720 hip
fracture elderly patients concluded that AA
genotype of the SLC6A3 gene (rs393795)
is protective for the development of
delirium while genetic polymorphisms
in the receptor DRD2 and dopamine
transporter genes, were associated with
delirium (rs6276, rs6277, and rs2734839)
(Munster et al., 2011). All seven SNPs in
the SLC6A3 gene were associated with
delirium; the gene affects the function of
dopamine transporters, effectively reduc-
ing the concentration of cerebral basal
dopamine and increasing delirium risk
(van Munster et al., 2010c). The rs6276
SNP has been associated with increased
alcohol use, which might be due to a lower
production rate, resulting in less D2 pro-
tein (Lucht et al., 2007). The rs6277 SNP
affects messenger RNA (mRNA) stability
and results in altered dopamine-induced
up regulation of DRD2 expression and
DRD2 mRNA translation (van Munster
et al., 2010c).
A further meta-analysis concluded that
the homozygous AA genotype of rs393795
in the SLC6A3 gene was more frequent
in patients without delirium, and the
homozygous GG genotype of rs6276 in the
DRD2 gene was more frequent in patients
without delirium after adjustment for cog-
nitive impairment (van Munster et al.,
2010b). The SLC6A3 gene could affect
availability or function of dopamine trans-
porters; lower cerebral basal dopamine
concentration could diminish risk for
delirium (van Munster et al., 2010b). The
rs393795 SNP is intronic, and intronic
sequences have been found to encode
microRNAs; future research could involve
sequencing this region for functional vari-
ants (van Munster et al., 2010b).
S-100B AND NEURON SPECIFIC
ENOLASE
Biomarkers of cerebral damage could
also potentially be used as a biomarker
of PD. S100B is elevated in blood and
cerebrospinal fluid (CSF) when ner-
vous system damage occurs as a result
www.frontiersin.org April 2014 | Volume 5 | Article 75 | 1
published: 16 April 2014
Stoicea et al. Delirium—biomarkers and genetic variance
of cerebral damage (van Munster et al.,
2009b). A postoperative elevation in
S100B levels in elderly hip fracture repair
patients has been observed in conjunction
with PD along with elevated postopera-
tive IL-6 and IL-8 serum concentrations in
the same population (van Munster et al.,
2009b). However, no link between IL-6
and IL-8 genetics and delirium has yet
been found (van Munster et al., 2011).
Interestingly, Olivecrona and Koskinen
found in 2012 that traumatic brain injury
(TBI) patients with the APOE ε4 allele
exhibited significantly higher maximal
levels of the S-100B protein than those
without the allele suggesting that there
is a genetic susceptibility to increased
levels of S-100B following a neurologic
insult (TBI in this case) (Olivecrona and
Koskinen, 2012). No similar study has
been conducted to examine the interplay
of genetics and S-100B in PD, so it is a
potential area for future research. In this
same study, Olivecrona and Koskinen,
found that neuron specific enolase (NSE)
was also elevated in TBI patients with the
Alzheimer’s disease related APOE ε4 allele
compared to those without (Olivecrona
and Koskinen, 2012). NSE has also been
examined in patients with PD, but no sig-
nificant correlation between elevated levels
of NSE and PD has yet been found (van
Munster et al., 2009b).
APOE ε4
Genetic variations in the apolipopro-
tein E have been studied in relation to
delirium. A study done by Ely et al.
including mechanically ventilated criti-
cally ill patients, examined the APOE4
polymorphism and its relationship with
delirium and discovered a strong associ-
ation between the APOE4 polymorphism
and a longer duration of delirium (Ely
et al., 2007). APOE4 is less effective at
suppressing nervous system inflammation
(Ely et al., 2007). Another study, survey-
ing various topics relating genetics and
delirium noted the APOE4 genotype is
associated with increased inflammation
in animal models, and that cytokines
can cause a reduction in the acetyl
cholinergic pathways (van Munster et al.,
2009a). Another article summarizing the
known biomarkers for delirium notes on
the inconsistencies in the outcomes of
APOE E4 studies (Chu et al., 2011). The
lack of notification of pre-existing cog-
nitive impairment in most studies pre-
vents definite association between the




The neuroadrenergic axis has been a
prominent focus of research on the etiol-
ogy of PD. PD is associated with elevated
cortisol and less frequent suppression of
IGF-I (Cerejeira et al., 2013). Similarly,
delirium is associated with higher lev-
els of cortisol in CSF measurements
(Pearson et al., 2010). Hip fracture patients
who were homozygous for BclI-TthIIII
haplotype (a haplotype associated with
increased sensitivity to glucocorticoids
and elevated diurnal cortisol levels) were
at a decreased risk of developing PD
(Manenschijn et al., 2011). One study
found no association between plasma glu-
cose and delirium, but did take note of
the hyperactivity of the HPA axis along
with high plasma and CSF cortisol lev-
els in patients with delirium compared
to those without (Bisschop et al., 2011).
This same study notes that delirium has
been reported in patients with Cushing’s
syndrome (characterized by excess corti-
sol), as well as in those undergoing gluco-
corticoid therapy (Bisschop et al., 2011).
Another study focused on the association
between serum composition and delirium
noted that HPA dysregulation in delirium
resulted in higher basal cortisol levels asso-
ciated with chronic cognitive impairment
and higher levels of cortisol under condi-
tions of acute stress; they concluded that
these acute elevations of cortisol could be
involved in development of delirium (van
Munster et al., 2010a).
ISCHEMIA
PD is a prominent cause of morbidity fol-
lowing hip arthroplasty, and cerebral fat
emboli often occur during the surgical
process—investigators have identified the
resulting cerebral ischemia as a potential
link worthy of investigation (Cox et al.,
2011).
There is extensive research on the
genetic biomarkers of cerebral ischemia.
MicroRNA-124 (miRNA-124) has been
reported to regulate differentiation of neu-
ral progenitor cells (Cheng et al., 2009). In
rats, a decrease in neurogenesis following
an induced ischemic stroke was associated
with decreased miRNA-124 expression
(Liu et al., 2011). There is evidence that a
reduced expression of miRNA-124 results
in decreased Ku70 expression and neu-
ronal death following ischemia and reper-
fusion injury (Zhu et al., 2014). Similarly,
there is also evidence that miRNA-124
plays a role in down regulating inflam-
matory cytokines (often indicated in
the pathogenesis of PD) (Deiner and
Silverstein, 2009; Sun et al., 2013). Further
research could elucidate a possible link
between the miR-124 molecular pathway
and PD. There are other miRNA associ-
ated with ischemic stroke and subsequent
neurogenesis, but they are not studied as
in depth as miR-124 (Yan et al., 2013).
SERUM ANTICHOLINERGIC ACTIVITY
Serum anticholinergic activity has also
been implicated in the pathogenesis of PD:
acetylcholinesterase (Ach) and butyryl-
cholinesterase (BuChE) are involved in the
production of inflammatory cytokines,
and are hypothesized to play a role in PD
development through this mechanism.
One study found significantly decreased
activity of these enzymes both preop-
eratively and postoperatively in patients
experiencing PD (Cerejeira et al., 2012).
Another study found a significant link
between lower cholinesterase activity
and increased inflammatory markers (C-
reactive protein, IL-6) (Cerejeira et al.,
2011). The finding of decreased pre-
operative cholinesterase activity in PD
patients suggests that cholinesterase activ-
ity could potentially be a predisposing
factor for PD. Cerejeira et al. men-
tioned that the preexisting difference in
anticholinergic activity could be due to
pharmacologic therapy, as well as overall
health, and genetic differences (Cerejeira
et al., 2012). The cholinergic system is
associated with a wide variety of physio-
logical processes in the brain that could
alter cognitive function (Cerejeira et al.,
2010). There are many polymorphisms
in the cholinesterase gene (Goodall,
2004). Cholinergic physiology has been
implicated in the pathophysiology of mul-
tiple neurodegenerative disorders (AD,
Parkinson’s) and inflammation related
diseases, and the complex genetics (includ-
ing both genetic polymorphisms and
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mi-RNA regulation) of the cholinergic
system have been proposed as a potential
area for identifying biomarkers of these
disorders (Shenhar-Tsarfaty et al., 2013).
Cholinesterase activity has been associated
with PD, so the investigation of biomark-
ers of cholinergic system dysfunction in
conjunction with PD is warranted.
CONCLUSIONS
The pathogenesis of PD is still poorly
understood. Further elucidation and
refinement of biomarkers to track the risk
and progression of this disorder would
help in the identification and treatment of
patients at risk for this devastating disor-
der. Future research should focus on both
identifying serummarkers of delirium and
understanding the genetic basis behind
these processes. Hopefully, these efforts
will make important strides in improv-
ing outcomes of patients experiencing
delirium.
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